Study of SCTT11 for thyroid eye disease
Part of Eyes & vision clinical trials.
This trial tests a new drug called SCTT11 in healthy people and in those with thyroid eye disease (TED) to see if it is safe and helpful. It may be an option if you have moderate-to-severe TED that affects your daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have moderate-to-severe thyroid eye disease that needs treatment but is not threatening your sight
- Your thyroid function is normal or only mildly off (free T3 and T4 levels less than 50% above or below normal)
- You are not pregnant, breastfeeding, and agree to use effective birth control during the study and for 180 days after the last dose
- You do not have other eye conditions, poorly controlled diabetes, high blood pressure, or other serious health problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called NTB003 for people with moderate-to-severe thyroid eye disease (TED). It aims to see if the drug can improve symptoms like eye bulging and double vision, and it may be an option for those whose disease is active or has been ongoing for a while.
This study tests a new medication called GenSci098 for people with active thyroid eye disease. It aims to reduce eye symptoms like redness, swelling, and bulging, and improve quality of life.
This study tests whether a new medicine called MHB018A can reduce swelling and inflammation in thyroid eye disease (TED)—a condition where the immune system attacks tissues around the eyes, causing them to swell, bulge, and become uncomfortable. Researchers will compare MHB018A to placebo (a fake medicine) to see if it helps improve symptoms and appearance.
This trial tests a new drug called MHB018A for chronic thyroid eye disease (TED)—a condition where the eyes become inflamed and swollen due to thyroid problems. The study aims to see if this treatment can reduce eye inflammation and improve symptoms in people who have had TED for over a year.
This trial tests a new drug, KHN939, for people with moderate-to-severe thyroid eye disease that is no longer active. It aims to see if the drug can improve symptoms like bulging eyes, eyelid retraction, or double vision.
This trial tests a new medication, KHN939, for people with moderate-to-severe active thyroid eye disease. It aims to reduce eye bulging and other symptoms.
Hear when a new TED trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.